Tag Archives: Anthony Vendetti

Nephros (NEPH) Receives a Buy from Maxim Group

Maxim Group analyst Anthony Vendetti maintained a Buy rating on Nephros (NEPH – Research Report) yesterday and set a price target of $16.00. The company’s shares closed last Monday at $9.90, close to its 52-week high of $11.35. According to

Landec (LNDC) Gets a Buy Rating from Maxim Group

Maxim Group analyst Anthony Vendetti maintained a Buy rating on Landec (LNDC – Research Report) yesterday and set a price target of $15.00. The company’s shares closed last Monday at $10.03. According to TipRanks.com, Vendetti is a 2-star analyst with

Ellex Medical Lasers (ELXMF) Receives a Buy from Maxim Group

Maxim Group analyst Anthony Vendetti maintained a Buy rating on Ellex Medical Lasers (ELXMF – Research Report) yesterday and set a price target of $1.00. The company’s shares closed last Monday at $0.38. According to TipRanks.com, Vendetti is a 2-star

Applied DNA Sciences (APDN) Receives a Buy from Maxim Group

In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on Applied DNA Sciences (APDN – Research Report), with a price target of $8.00. The company’s shares closed last Monday at $3.94, close to its 52-week

BioPharmX (BPMX) Gets a Buy Rating from Maxim Group

In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on BioPharmX (BPMX – Research Report), with a price target of $1.00. The company’s shares closed last Monday at $0.38, close to its 52-week low of

Maxim Group Remains a Buy on Ra Medical Systems (RMED)

Maxim Group analyst Anthony Vendetti maintained a Buy rating on Ra Medical Systems (RMED – Research Report) yesterday and set a price target of $3.00. The company’s shares closed last Monday at $1.28, close to its 52-week low of $1.06.